Zacks: Analysts Anticipate XOMA Corporation (NASDAQ:XOMA) Will Post Quarterly Sales of $10.56 Million

Wall Street analysts expect that XOMA Corporation (NASDAQ:XOMA) will post sales of $10.56 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for XOMA Corporation’s earnings, with estimates ranging from $10.24 million to $10.87 million. XOMA Corporation posted sales of $440,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 2,300%. The business is expected to announce its next earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that XOMA Corporation will report full year sales of $10.56 million for the current financial year, with estimates ranging from $11.25 million to $13.17 million. For the next financial year, analysts forecast that the company will post sales of $7.78 million per share, with estimates ranging from $4.60 million to $10.95 million. Zacks’ sales averages are an average based on a survey of research firms that follow XOMA Corporation.

XOMA has been the topic of a number of research analyst reports. Zacks Investment Research raised XOMA Corporation from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Friday, July 14th. HC Wainwright initiated coverage on XOMA Corporation in a research note on Monday, June 12th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $10.67.

XOMA Corporation (XOMA) traded down 0.28% during mid-day trading on Friday, reaching $7.19. The company had a trading volume of 29,244 shares. The stock has a 50 day moving average of $7.00 and a 200 day moving average of $6.17. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $13.98. The stock’s market capitalization is $54.54 million.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate XOMA Corporation (NASDAQ:XOMA) Will Post Quarterly Sales of $10.56 Million” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/zacks-analysts-anticipate-xoma-corporation-nasdaqxoma-will-post-quarterly-sales-of-10-56-million-updated-updated.html.

In related news, Director John Varian sold 39,540 shares of XOMA Corporation stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $6.24, for a total transaction of $246,729.60. Following the transaction, the director now owns 2,344 shares in the company, valued at $14,626.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 3.92% of the company’s stock.

A hedge fund recently bought a new stake in XOMA Corporation stock. Stonepine Capital Management LLC acquired a new position in XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation accounts for approximately 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 19th largest position. Stonepine Capital Management LLC owned 1.17% of XOMA Corporation as of its most recent filing with the SEC. 31.21% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Corporation

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA Corporation (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA Corporation (NASDAQ:XOMA)

What are top analysts saying about XOMA Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for XOMA Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit